Theriva Biologics (TOVX) Total Liabilities (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Total Liabilities of $22.8 million for Q1 2026, up 37.12% year-over-year from $16.7 million in Q1 2025, and little changed quarter-over-quarter from $22.9 million in Q4 2025.
Theriva Biologics (TOVX) Total Liabilities (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Total Liabilities for 17 consecutive years, with $22.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 37.12% year-over-year to $22.8 million; the TTM figure through Mar 2026 stood at $22.8 million (up 37.12% YoY), while the FY2025 annual figure was $22.9 million, up 40.35% from the prior year.
- Total Liabilities steadied at $22.8 million in Q1 2026 per TOVX's latest filing, from $22.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $25.2 million in Q2 2025 and bottomed at $14.6 million in Q1 2024.
- Historically, Total Liabilities has averaged $18.6 million across 5 years, with a median of $17.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 840.45% — and 2023, when it retreated 17.51%.
- Theriva Biologics' Total Liabilities stood at $17.3 million in 2022, then slipped by 10.26% to $15.5 million in 2023, then climbed by 4.92% to $16.3 million in 2024, then jumped by 40.35% to $22.9 million in 2025, then slipped by 0.03% to $22.8 million in 2026.
- Business Quant data shows TOVX's Total Liabilities at $22.8 million in Q1 2026, $22.9 million in Q4 2025, and $24.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Theriva Biologics | 10.90 Mn | 10.90 Mn | - | 22.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.67 Mn |
| Mar 31, 2026 | 22.85 Mn |
| Dec 31, 2025 | 22.86 Mn |
| Sep 30, 2025 | 24.10 Mn |
| Jun 30, 2025 | 25.21 Mn |
| Mar 31, 2025 | 16.66 Mn |
| Dec 31, 2024 | 16.29 Mn |
| Sep 30, 2024 | 15.47 Mn |
| Jun 30, 2024 | 14.74 Mn |
| Mar 31, 2024 | 14.61 Mn |
| Dec 31, 2023 | 15.52 Mn |
| Sep 30, 2023 | 17.66 Mn |
| Jun 30, 2023 | 17.70 Mn |
| Mar 31, 2023 | 17.30 Mn |
| Dec 31, 2022 | 17.30 Mn |
| Sep 30, 2022 | 17.99 Mn |
| Jun 30, 2022 | 18.42 Mn |
| Mar 31, 2022 | 20.97 Mn |
| Dec 31, 2021 | 4.96 Mn |
| Sep 30, 2021 | 4.56 Mn |